AMNI — Amniotics AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK14.64m
- SEK9.00m
Brief: Amniotics Receives Positive Topline Results From Clinical Phase Ib Study With Pulmostem
Brief: Amniotics Q1 Operating Loss SEK 10.8 Million
Brief: Amniotics Reports Q1 EBITDA of SEK -10.8 Million
Brief: Amniotics Appoints Gerton Jönsson As CFO
Brief: Amniotics To Receive SEK 25.3 Mln From Rights Issue
Brief: Amniotics Gets Positive Information About Safety Data For Pulmostem In Clinical Study
Brief: Amniotics Q4 Operating Loss Narrows To SEK 9.8 Million
Brief: Amniotics Changes Its Strategic Direction, Implements Cost-Saving Measures
Brief: Amniotics Resolves On Rights Issue Of About SEK 36.1 Mln
Brief: Amniotics Led Consortium Gets European Innovation Council Grant
Brief: Amniotics Q3 EBITDA Loss Widens To SEK 15.3 Million
Brief: Amniotics Receives U.S. Patent For Its Oncology Program AMNI-NK003
Brief: Amniotics To Expand Clinical Indications In Phase Ib Study Of Pulmostemtm
Brief: Amniotics Appoints Marcus Larsson As New CEO
Brief: Amniotics Q2 EBITDA Loss Narrows To SEK 10.2 Mln
Brief: Amniotics Granted U.S. Patent For Pulmostem
Brief: Amniotics Presents Positive Preclinical Data
Brief: Amniotics Gets Loan Of SEK 15 MLN
Brief: Amniotics Announces Positive Pre-Clinical Proof-Of-Concept Results For Pulmostem In End-Stage Lung Disease